Trusted Resource for Clinical Trials, Protocols & Progress
What Happens in a Phase 2 Clinical Trial? Understanding the Structure and Purpose of Phase 2 Clinical Trials Introduction Phase 2 clinical trials are a pivotal part of the drug development process. After a new drug or therapy demonstrates basic safety in Phase 1, it moves to Phase 2 to assess its effectiveness in treating…
Introduction to Phase 1 Clinical Trials: Scope, Purpose, and Regulatory Role Introduction to Phase 1 Clinical Trials: Scope, Purpose, and Regulatory Role What Are Phase 1 Clinical Trials? Phase 1 clinical trials are the first stage of human testing in the drug development process. Often referred to as first-in-human (FIH) studies, they focus primarily on…
Read More “Introduction to Phase 1 Clinical Trials: Scope, Purpose, and Regulatory Role” »
What are Phase 4 (Post-Marketing) Clinical Trials? A Complete Overview for Clinical Researchers Understanding Phase 4 Clinical Trials: What Happens After Drug Approval What Are Phase 4 Trials and Why Are They Conducted? Phase 4 clinical trials, often referred to as post-marketing studies, are conducted after a drug or therapy has received regulatory approval and…
Phase 0 vs. First-in-Human Trials: How to Transition Effectively Phase 0 vs. First-in-Human Trials: Transitioning Safely from Microdosing to Therapeutic Dosing Introduction Phase 0 trials offer early insight into drug behavior in humans using sub-therapeutic microdoses. First-in-Human (FIH) trials, on the other hand, initiate therapeutic dosing to assess safety and tolerability. Bridging the gap between…
Read More “Phase 0 vs. First-in-Human Trials: How to Transition Effectively” »
Combining Phase 0 with Adaptive Phase 1 Trials: Strategies for Seamless Transition Combining Phase 0 and Adaptive Phase 1 Trials: A Seamless Early Development Strategy Introduction Phase 0 trials provide early human pharmacokinetic and target engagement data. Phase 1 trials explore safety and dose tolerance. Combining these phases into a seamless development strategy using adaptive…
Read More “Combining Phase 0 with Adaptive Phase 1 Trials: Strategies for Seamless Transition” »
PET Imaging and Radiolabeling Techniques in Phase 0 Oncology Studies Using PET Imaging and Radiolabeling in Phase 0 Oncology Trials Introduction Phase 0 oncology trials aim to generate early human data to guide therapeutic development. One of the most powerful tools in these trials is Positron Emission Tomography (PET) imaging, especially when paired with radiolabeled…
Read More “PET Imaging and Radiolabeling Techniques in Phase 0 Oncology Studies” »
Common Pitfalls in Phase 0 Trial Design and How to Avoid Them Common Pitfalls in Phase 0 Trial Design and How to Avoid Them Introduction Phase 0 trials are small, fast, and cost-effective—but they must be carefully designed to yield meaningful data. Because these microdosing studies are non-therapeutic, researchers sometimes underestimate their complexity. Design missteps…
Read More “Common Pitfalls in Phase 0 Trial Design and How to Avoid Them” »
Writing SOPs and Protocols for GLP-Compliant Phase 0 Trials How to Write Protocols and SOPs for GLP-Compliant Phase 0 Trials Why GLP Matters in Phase 0 Microdosing Studies Although Phase 0 trials involve human subjects and follow GCP, they also rely heavily on nonclinical data, analytical labs, and sample handling—all of which fall under Good…
Read More “Writing SOPs and Protocols for GLP-Compliant Phase 0 Trials” »
Integrating In Silico Modeling and PBPK with Phase 0 Studies Integrating In Silico Modeling and PBPK with Phase 0 Studies Introduction: Enhancing Predictive Power of Early Trials Phase 0 trials offer real human PK data at microdose levels—but alone, they can’t predict full-dose behavior for every compound. To bridge this gap, researchers increasingly rely on…
Read More “Integrating In Silico Modeling and PBPK with Phase 0 Studies” »
Global Regulatory Landscape for Phase 0 Studies: A Comparative Guide Global Regulatory Landscape for Phase 0 Clinical Trials: A Comparative Overview Introduction: Regulatory Oversight in Early Human Studies Phase 0 trials—or exploratory microdosing studies—may be low-risk, but they are still subject to stringent regulatory oversight. Each country has unique pathways for approval, risk classification, and…
Read More “Global Regulatory Landscape for Phase 0 Studies: A Comparative Guide” »
